Tsai-Ta Lai
Fortune : 189 M $ au 31/07/2026
Fortune : 189 M $ au 31/07/2026
Tsai-Ta Lai held the position of Chief Technology Officer at AquaFresco, Inc., founded in 2015.
Dr. Lai is Chairman & Chief Executive Officer at Metis TechBio Co., Ltd., founded in 2020.
Dr. Lai is the founder of AquaFresco, Inc. (2015) and Metis TechBio Co., Ltd. (2020).
Dr. Lai is also the founder of METiS Therapeutics, Inc...
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 10/06/2026 | 111 166 572 ( 10,26 % ) | 143 M $ | 31/07/2026 | |
METIS TECHBIO CO., LTD. 36,55 % | 13/05/2026 | 36 400 278 ( 36,55 % ) | 47 M $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| METIS TECHBIO CO., LTD. | Directeur Général | 10/01/2020 |
METiS Therapeutics, Inc.
METiS Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for patients with diseases | Directeur Général | - |
| Sociétés | Poste | Fin |
|---|---|---|
AquaFresco, Inc.
AquaFresco, Inc. Industrial MachineryProducer Manufacturing Designs and develops water recycling technology | Fondateur | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 3 |
|---|---|
AquaFresco, Inc.
AquaFresco, Inc. Industrial MachineryProducer Manufacturing Designs and develops water recycling technology | Producer Manufacturing |
METiS Therapeutics, Inc.
METiS Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for patients with diseases | Health Technology |
Hangzhou Jitai Pharmaceutical Technology Co. Ltd.
Hangzhou Jitai Pharmaceutical Technology Co. Ltd. Chemicals: Major DiversifiedProcess Industries Operates as an investment holding company whose subsidiaries provides AI based nanomaterials delivery and application services | Process Industries |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national